Annual School of Nursing Oncology
Approaches to Urothelial Care Call for Nuanced AE Management
August 11, 2022
Article
Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.
Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell Carcinoma
August 10, 2022
Article
In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.
Molecular Profiling Is a Necessity in Colorectal Cancer Treatment
August 09, 2022
Article
At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
August 08, 2022
Video
Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.
Nurses Adapt to New Hematology Advances and Approvals in Leukemia Treatment
August 08, 2022
Article
Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
August 05, 2022
Video
Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.
Targeted Therapy Approvals Improve Outcomes, Expand Options for Patients With NSCLC
August 04, 2022
Article
At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.
Nurses Play Key Role in Facilitating Maintenance Therapy With PARP Inhibitors in Ovarian Cancer
August 02, 2022
Article
Paula Anastasia, RN, MN, AOCN, discusses the value of germline testing and the role of maintenance PARP inhibitor therapy in optimized ovarian cancer treatment.
Rone Discusses Exciting Immunotherapy Research in Gastrointestinal Cancer
August 02, 2022
Article
Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.
Nurse Navigators Can Help Alleviate Medical Distrust, Improve Clinical Trial Enrollment
August 01, 2022
Article
Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.